ReviewViruses2024
Current Progress of Severe Fever with Thrombocytopenia Syndrome Virus (SFTSV) Vaccine Development.
Review in Viruses, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 40 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
40 citing papers in PubMed, 2 syntheses or guidelines pooled it, 31 citations in OpenAlex.
- Global trends in tick research: a comprehensive visualization and bibliometric study (2015-2024).Frontiers in cellular and infection microbiology · 2025Pooled it
- Knowledge mapping of severe fever with thrombocytopenia syndrome: a bibliometric analysis.Frontiers in microbiology · 2024Pooled it
- Article
- Evaluation of new adjuvants in enhancing the immune response to a candidate of Severe Fever with Thrombocytopenia Syndrome Virus vaccine.bioRxiv : the preprint server for biology · 2026Article
- Droplet digital PCR-based nucleic acid amplification test for improved molecular and clinical diagnosis of severe fever with thrombocytopenia syndrome patients.Journal of clinical microbiology · 2026Article
- Genomic and phylogenetic characterization of severe fever with thrombocytopenia syndrome virus in companion animals in Korea, 2023-2024.PLoS neglected tropical diseases · 2026Article
- CD163⁺ monocytes and soluble CD163 as prognostic indicators in severe fever with thrombocytopenia syndrome: An integrative analysis.PLoS neglected tropical diseases · 2026Article
- A study on antibody persistence following severe fever with thrombocytopenia syndrome virus infection in the Dabie Mountain Region, China.BMC infectious diseases · 2026Article
- Article
- Targeting the lethal weakness of SFTSV: Latest advances in antiviral strategies and immune prevention.iScience · 2026Review
- Ticks and tick-borne diseases: A call for comprehensive tick surveillance in India under One Health approach.The Indian journal of medical research · 2026Review
- Genotype-Dependent Virulence of Severe Fever with Thrombocytopenia Syndrome Virus in a Mouse Challenge Model.International journal of molecular sciences · 2026Article
- Development of a Prophylactic mRNA Vaccine for Severe Fever with Thrombocytopenia Syndrome Using HSA based LNP.NPJ vaccines · 2026Article
- Immune Cells at the Frontline of SFTSV Infection.Journal of microbiology and biotechnology · 2026Review
- SFTSV: a priority pathogen in need of a cure-reviewing the therapeutic.Archives of microbiology · 2026Review
- Recombinant Dabie bandavirus as a bivalent vaccine platform inducing protective immunity against intracellular pathogens and cancer.Molecular therapy : the journal of the American Society of Gene Therapy · 2026Article
- Metatranscriptomics profiling reveals rodent- and shrew-borne viral diversity and evolutionary relationships in Guangzhou, China.Virologica Sinica · 2026Article
- Genetic characterization of severe fever with thrombocytopenia syndrome virus in ticks from livestock environments in South Korea.Frontiers in microbiology · 2026Article
- Development and validation of an interpretable machine learning model for the early diagnosis of invasive pulmonary aspergillosis in patients with severe fever with thrombocytopenia syndrome: a retrospective cohort study.Frontiers in cellular and infection microbiology · 2026Article
- Multi-Epitope mRNA Vaccine TargetingBioinformatics and biology insights · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
Abstract
SFTSV is an emerging tick-borne virus causing hemorrhagic fever with a case fatality rate (CFR) that can reach up to 27%. With endemic infection in East Asia and the recent spread of the vector tick to more than 20 states in the United States, the SFTSV outbreak is a globally growing public health concern. However, there is currently no targeted antiviral therapy or licensed vaccine against SFTSV. Considering the age-dependent SFTS pathogenesis and disease outcome, a sophisticated vaccine development approach is required to safeguard the elderly population from lethal SFTSV infection. Given the recent emergence of SFTSV, the establishment of animal models to study immunogenicity and protection from SFTS symptoms has only occurred recently. The latest research efforts have applied diverse vaccine development approaches-including live-attenuated vaccine, DNA vaccine, whole inactivated virus vaccine, viral vector vaccine, protein subunit vaccine, and mRNA vaccine-in the quest to develop a safe and effective vaccine against SFTSV. This review aims to outline the current progress in SFTSV vaccine development and suggest future directions to enhance the safety and efficacy of these vaccines, ensuring their suitability for clinical application.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.